Organization
BC Cancer Centre for Lymphoid Cancer
4 abstracts
Abstract
Final results of a first-in-human phase I dose escalation trial of daily oral zelenirstat, a n-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas.Org: BC Cancer Centre for Lymphoid Cancer, Pacylex Pharmaceuticals, Inc.,
Abstract
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.Org: Levine Cancer Institute, Wilmot Cancer Institute, BC Cancer Centre for Lymphoid Cancer, Willamette Valley Cancer Institute and Research Center, US Oncology Research,
Abstract
Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.Org: City of Hope National Medical Center, Genentech, BC Cancer Centre for Lymphoid Cancer, Centre Henri-Becquerel and University of Rouen, University Hospital Münster,
Abstract
A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors.Org: Cross Cancer Institute, Centre Hospitalier de l’Université de Montréal/CRCHUM, Princess Margaret - University Health Network, BC Cancer Centre for Lymphoid Cancer, Pacylex Pharmaceuticals, Inc.,